Market Cap
$1.9B
ZYME
Zymeworks Inc.
$25.15 ▼ -3.12%
Prev close $25.96Market cap$1.9B
ConsensusStrong Buy
12-mo target$41.07 (+63.3%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (8/10)10 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ZYME right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$801.8M
Inst. Activity
10 buys / 18 sells
Social Sentiment
67° Warm
SEC Reports
5
Press Releases
7
Price chart 30d -15.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 m_and_a
Aug 25, 2026 SEC Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a bio
Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii)-conta
8-K — Impact 8/10
Aug 5, 2026 Event
Jul 16, 2026 SEC HSR Early Termination: Zymeworks Inc.; Theravance Biopharma, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Zymework
Zymeworks reported Q1 2026 EPS of -$0.59, a 31.6% miss versus consensus of -$0.45, with revenue of $18.1M in line with e
PRESS-RELEASE — Impact 6/10
Jul 6, 2026 Insider
Hollywood Mark was granted 939 shares
EVP & Chief Operating Officer @ $22.22 ($20.9K)
Jun 30, 2026 Inst.
Assenagon Asset Management S.A. — ADD
1,252,027 shares ($32.7M)
Jun 30, 2026 Inst.
Jun 29, 2026 Press NOMURA ASSET MANAGEMENT INTERNATIONAL — NEW
889,802 shares ($23.3M)
Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance Biopharma (TBPH) for $17.00 per share, or approximate
Impact 7/10
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Sep 17, 2026 | Wolfe Research | INITIATE | Outperform | 52% |
| Sep 3, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 26, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 26, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Aug 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 10, 2026 | B. Riley Securities | REITERATE | Buy | 54% |
| Aug 7, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 7, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% |
Price targets
Where 14 covering analysts think ZYME trades over the next 12 months.
$41.07 +63.3% upside Strong Buy
Current$25.15 Low$32.00 Median$38.00 High$60.00 14 analysts
$32.00$60.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 3 neutral · avg impact 4.4/10.Plus 7 press releases.
BULLISH8-K8/10
Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zan
Aug 25, 2026
BEARISHPRESS-RELEASE6/10
Zymeworks reported Q1 2026 EPS of -$0.59, a 31.6% miss versus consensus of -$0.45, with revenue of $
Jul 16, 2026
NEUTRAL32/10
Form 3 filing for Paul R. Schneider, EVP and General Counsel of Zymeworks Inc., reports zero benefic
May 15, 2026
NEUTRALPRESS-RELEASE3/10
Zymeworks announced it will report Q1 2026 financial results on May 7, 2026, with no actual financia
Apr 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
m_and_a
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of license
Sep 23, 2026
m_and_a
Zymeworks Completes Acquisition of Theravance Biopharma
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of license
Aug 26, 2026
short_volume
Short Volume: ZYME — 60.4% short (0.3M / 0.5M)
Short: 317,624 | Exempt: 27,638 | TRF Vol: 526,145 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Aug 25, 2026
fda_pdufa
PDUFA: ZYME — Ziihera in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) — 2026-08-25
FDA target action date 2026-08-25 for ZYME (Zymeworks Inc.). Drug: Ziihera. Indication: first-line HER2-positive unresectable locally advanced or meta
Aug 25, 2026
short_volume
Short Volume: ZYME — 61.2% short (0.5M / 0.9M)
Short: 538,535 | Exempt: 12,966 | TRF Vol: 880,509 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.07 | $-0.57–$3.29 | 897.0% | -7.4% | 1↑ 0↓ | $0.2B | 6 |
| Next Q | $-0.00 | $-0.81–$2.51 | 99.3% | -101.9% | 0↑ 2↓ | $0.1B | 6 |
| Current FY | $0.89 | $0.25–$1.75 | 182.6% | -24.6% | 1↑ 2↓ | $0.3B | 7 |
| Next FY | $0.87 | $-1.29–$4.17 | -2.2% | -25.2% | 1↑ 2↓ | $0.4B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.072 | — |
| 7d ago | $2.288 | -0.216 |
| 30d ago | $2.238 | -0.166 |
| 60d ago | $2.602 | -0.530 |
| 90d ago | $1.658 | +0.414 |
Institutional ownership
Which big funds own ZYME (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $801.8M total value (30,703,718 shares) as of 2026-Q2. Top holders: Rubric, BlackRock,, MORGAN. Net selling activity: 18 institutions trimmed/exited vs 10 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Rubric Capital Management LP | 7,000,000 | $183.0M | 22.8% | — |
| BlackRock, Inc. | 4,251,030 | $111.1M | 13.9% | — |
| MORGAN STANLEY | 2,231,260 | $58.3M | 7.3% | — |
| BNP Paribas Asset Management Holding S.A. | 1,781,116 | $46.6M | 5.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,558,998 | $40.8M | 5.1% | — |
| Assenagon Asset Management S.A. | 1,252,027 | $32.7M | 4.1% | ADD +72.0% |
| STATE STREET CORP | 1,088,216 | $28.4M | 3.5% | — |
| DIMENSIONAL FUND ADVISORS LP | 994,955 | $26.0M | 3.2% | — |
| CITADEL ADVISORS LLC | 914,136 | $23.9M | 3.0% | — |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 889,802 | $23.3M | 2.9% | NEW |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | ADD | 727,986 | 1,252,027 | +72.0% | $32.7M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | NEW | — | 889,802 | — | $23.3M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 743,898 | 418,497 | -43.7% | $10.9M |
| DEUTSCHE BANK AG\ | TRIM | 921,250 | 397,190 | -56.9% | $10.4M |
| Pictet Asset Management Holding SA | DOUBLED | 9,256 | 308,187 | +3229.6% | $7.4M |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | ADD | 163,649 | 223,766 | +36.7% | $5.8M |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 66,106 | 155,579 | +135.3% | $4.1M |
| D. E. Shaw & Co., Inc. | TRIM | 235,621 | 144,807 | -38.5% | $3.8M |
| Nuveen, LLC | NEAR_EXIT | 651,662 | 119,389 | -81.7% | $3.1M |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 206,854 | 118,603 | -42.7% | $3.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 12 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Hollywood Mark | EVP & Chief Operating Officer | AWARD | 939 | $22.22 | $20.9K |
| May 13, 2026 | Schneider Paul R | EVP, General Counsel | AWARD | 178,000 | — | — |
| May 13, 2026 | Schneider Paul R | EVP, General Counsel | AWARD | 119,000 | — | — |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | AWARD | 70,000 | — | — |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | AWARD | 76,000 | — | — |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | AWARD | 70,000 | — | — |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | AWARD | 47,000 | — | — |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | AWARD | 47,000 | — | — |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | AWARD | 76,000 | — | — |
| Apr 6, 2026 | Stafford Kristin | EVP, Chief Financial Officer | AWARD | 178,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ZYME.
Shares short
4,939,072
Settlement Sep 15, 2026
Change vs prior
+4.5%
Semi-monthly cycle
Days to cover
8.0
At avg daily volume
Of shares outstanding
≈7.0%
Estimate — not % of float
All ZYME filing & press-release reports (12)
- 8-K reportAug 25, 2026
- PRESS-RELEASE reportJul 16, 2026
- PRESS-RELEASE reportJun 29, 2026
- PRESS-RELEASE reportJun 14, 2026
- 3 reportMay 15, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 16, 2026
- 3 reportApr 10, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 2, 2026
- PRESS-RELEASE reportMar 2, 2026